Table of contents
- Trial overview
- Study population and who may participate
- Trial design and phase
- What the trial measures
- Vaccine comparisons used in the study
- Simple explanation of key terms
Trial overview
This authorised Phase 2 study is an interventional trial with 750 participants.[1] The trial data provided describe a study in healthy children, toddlers, and infants, and the main goal is to describe the safety profile and immune response to the study vaccine formulations.[1]
The listed condition is meningococcal immunization, which means the study is focused on vaccination against meningococcal disease.[1] The brief summary also says the study compares MenPenta vaccine formulations with comparator vaccines across different pediatric stages.[1]
Study population and who may participate
The trial includes three age-based stages: healthy children in Stage 1, toddlers in Stage 2, and infants in Stage 3.[1] This means the study is not for the general population, but for young participants in specific age groups.[1]
In the infant stage, the trial looks at immune response after the second dose given at about 4 months of age and after the third dose given at 12 to 15 months of age.[1] For children and toddlers, the study measures immune response at each time point after vaccination.[1]
Trial design and phase
The study is interventional, which means participants receive vaccines as part of the research plan rather than only being observed.[1] It is in Phase 2, a stage that usually helps researchers learn more about safety and how the immune system responds in a larger group.[1]
The status is Authorised, showing that the study has been approved to proceed in the source record.[1] The study size is 750 participants, which is large enough to compare immune responses across the pediatric groups listed in the trial.[1]
What the trial measures
The main safety outcomes include the number of participants with unsolicited immediate adverse events, solicited injection site reactions or systemic reactions, unsolicited adverse events, and serious adverse events.[1] These outcomes help researchers see both common short-term reactions and more serious medical problems during the study.[1]
The immune outcomes focus on hSBA antibody titers, vaccine seroresponse, and geometric mean titers against meningococcal serogroups A, C, W, Y, and reference MenB strains.[1] In simple terms, the study checks how strong the blood’s ability is to help kill the bacteria after vaccination.[1]
For infants, the study measures these immune results before dosing and 30 days after the second and third doses, including the percentage of participants with antibody levels at or above the lower limit of quantification.[1] For children and toddlers, the same type of antibody testing is used to compare immune response after vaccination.[1]
Vaccine comparisons used in the study
The intervention list shows several vaccines used as comparators or related study products, including MenQuadfi, Bexsero, Nimenrix, Prevenar 13, Hexyon, RotaTeq, MenPenta SD, and MenPenta fHD.[1] The trial summary says the study evaluates MenPenta formulations against comparator vaccines.[1]
These comparisons help researchers understand whether the study vaccine formulations produce the desired immune response and how their safety profile looks in different age groups.[1]
Simple explanation of key terms
Solicited reactions are side effects that the study specifically asks about, such as reactions at the shot site or symptoms affecting the whole body.[1] Unsolicited adverse events are any other medical events that happen during the study and are reported even if they were not expected.[1]
Seroresponse means the blood shows a meaningful rise in antibodies after vaccination.[1] GMT, or geometric mean titer, is a way to show the average antibody level in the group.[1]
hSBA is a lab test that checks whether antibodies can help kill meningococcal bacteria.[1] The terms A, C, W, Y, and MenB refer to different meningococcal groups being measured in the study.[1]
